| pubmed-article:15764218 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15764218 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15764218 | lifeskim:mentions | umls-concept:C1266002 | lld:lifeskim |
| pubmed-article:15764218 | lifeskim:mentions | umls-concept:C0220650 | lld:lifeskim |
| pubmed-article:15764218 | lifeskim:mentions | umls-concept:C1273404 | lld:lifeskim |
| pubmed-article:15764218 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:15764218 | lifeskim:mentions | umls-concept:C0449450 | lld:lifeskim |
| pubmed-article:15764218 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15764218 | pubmed:dateCreated | 2005-3-14 | lld:pubmed |
| pubmed-article:15764218 | pubmed:abstractText | The purpose of this study was retrospectively to evaluate the effectiveness of fractionated stereotactic radiotherapy (FSRT) for patients who presented with intracranial metastases as the initial symptom of lung carcinoma. Fifteen patients with three or fewer brain metastases from lung carcinoma underwent FSRT receiving 42 Gy in 7 fractions or 40 Gy in 4 fractions from April 1999 to October 2002. Patients who developed new lesions were retreated with FSRT or whole brain radiotherapy (WBRT). Tumor control was obtained in 14 patients during a median period of 21.0 months (ranging from 11 to 34 months) with salvage radiotherapy whenever required. None died from brain metastasis. The median survival time was 7.0+/-3.0 months and 21.0+/-1.0 months for patients with or without extracranial metastases, respectively (p<0.01). Those who received treatment for the primary and mediastinal lymph nodes (22.0+/-1.4 months) survived longer than those who did not (8.0+/-2.5 months) (p<0.001). Overall high local control and high survival rates for the patients suggest that FSRT appears effective and safe in the treatment of patients who present with intracranial metastases as the initial symptom of lung carcinoma. After treatment of intracranial metastases, further therapy for the primary appears to improve survival rates. | lld:pubmed |
| pubmed-article:15764218 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15764218 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15764218 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15764218 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15764218 | pubmed:issn | 0284-186X | lld:pubmed |
| pubmed-article:15764218 | pubmed:author | pubmed-author:NakayamaHidet... | lld:pubmed |
| pubmed-article:15764218 | pubmed:author | pubmed-author:IshikawaHiroi... | lld:pubmed |
| pubmed-article:15764218 | pubmed:author | pubmed-author:ShiotaniSeiji... | lld:pubmed |
| pubmed-article:15764218 | pubmed:author | pubmed-author:TokuuyeKoichi... | lld:pubmed |
| pubmed-article:15764218 | pubmed:author | pubmed-author:AkineYasuyuki... | lld:pubmed |
| pubmed-article:15764218 | pubmed:author | pubmed-author:KomatsuYoujiY | lld:pubmed |
| pubmed-article:15764218 | pubmed:author | pubmed-author:NakadaYoshita... | lld:pubmed |
| pubmed-article:15764218 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15764218 | pubmed:volume | 43 | lld:pubmed |
| pubmed-article:15764218 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15764218 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15764218 | pubmed:pagination | 736-9 | lld:pubmed |
| pubmed-article:15764218 | pubmed:dateRevised | 2009-5-12 | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:meshHeading | pubmed-meshheading:15764218... | lld:pubmed |
| pubmed-article:15764218 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15764218 | pubmed:articleTitle | Stereotactic radiotherapy for patients who initially presented with brain metastases from non-small cell carcinoma. | lld:pubmed |
| pubmed-article:15764218 | pubmed:affiliation | Tsukuba Medical Center, Department of Radiation Oncology, Tukuba, Ibaraki, Japan. hnakayama@tmch.or.jp | lld:pubmed |
| pubmed-article:15764218 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15764218 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
